BioCardia, Inc. Regains Nasdaq Minimum Bid Price Compliance

What Happened BioCardia, Inc. (BCDA) filed an 8-K on September 21, 2026, reporting that Nasdaq's Listing Qualifications Staff has determined the company has regained compliance with the Nasdaq Capital Market minimum bid price requirement. Nasdaq notified the company that the closing bid price of BCDA common stock had been $1.00 or greater for at least 10 consecutive business days, and the deficiency matter is now closed.

Key Details

• Nasdaq initially notified BioCardia on August 19, 2026 that the company's stock had traded below the $1.00 minimum for the prior 30 consecutive business days.
• On September 21, 2026, Nasdaq confirmed compliance after at least 10 consecutive business days with a closing bid of $1.00 or more.
• Trading of BioCardia common stock is unaffected and continues on the Nasdaq Capital Market under the ticker symbol "BCDA."
• The 8-K includes the company’s standard forward-looking statement caution that regaining compliance does not guarantee it can be maintained in the future.

Why It Matters Regaining compliance avoids a potential delisting process, preserving BioCardia’s continued listing on Nasdaq and maintaining normal trading access and visibility for investors. However, the company notes there is no assurance it will remain in compliance going forward, so investors should monitor the stock price and company disclosures for future updates.